Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neisseria meningitidis polysaccharide serogroup Y antigen
- Molecular classification
- Polysaccharide antigen, Bacterial capsular polysaccharide, Microbial virulence factor
01
Overview
Neisseria meningitidis polysaccharide serogroup Y antigen is a repeating disaccharide capsular polysaccharide composed of →6)-α-D-glucose(1→4)-α-D-N-acetylneuraminic acid(2→ linkages. The capsule is the main virulence determinant, protecting the bacterium from complement-mediated lysis and phagocytosis. Antibodies against the group Y polysaccharide are protective, and the antigen is included in multivalent meningococcal conjugate vaccines (e.g., MenACWY), which provide immunity against invasive disease caused by serogroup Y. Capsule switching via genetic exchange can affect vaccine efficacy and disease surveillance. The three-dimensional structure exposes both hydrophilic and hydrophobic surfaces, affecting antibody binding and specificity.
- Other names
- Serogroup Y capsular polysaccharideGroup Y polysaccharide antigenGYMP
02
Mechanism of action
Vaccines: Induce formation of antibodies that bind the polysaccharide, promoting complement-mediated killing and opsonization
03
Biological functions
Immune evasion (protection against complement-mediated killing)Virulence determinantBasis for serogroup classificationInduces antibody responses used in vaccine development
04
Disease associations
Infection (major cause of invasive meningococcal disease)
05
Safety considerations
Potential for capsule switching (genetic exchange leading to change in serogroup, allowing immune escape)Low immunogenicity in infants and young children when unconjugated; resolved by conjugate vaccinesNo direct toxicity but a challenge in reliable immune response due to structural similarity to human glycoproteins, minimizing cross-reactivity
06
Interacting drugs
Meningococcal conjugate vaccines (e.g., MenACWY, containing purified or conjugated serogroup Y polysaccharide)
07
Biomarkers
Anti-serogroup Y polysaccharide IgG titers (used to monitor immune response after vaccination or infection)
Beyond the preview
Go deeper on Neisseria meningitidis polysaccharide serogroup Y antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis polysaccharide serogroup Y antigen.